Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis

Clinical and Experimental Immunology

Volumn 133, Issue 1, 2003, Pages 132-138

  Ho, C Y ^a   Wong, C K ^a   Li, E K ^a   Tam, L S ^a   Lam, C W K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Leflunomide; MCP 1; MDC; Rheumatoid arthritis; TARC

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; COMPLEMENTARY DNA; CORTICOSTEROID; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 15; LEFLUNOMIDE; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RHEUMATOID FACTOR; RNA; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; DNA PROBE; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATORY CELL; MALE; MONONUCLEAR CELL; PAIN ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; CHEMOKINE CCL2; CHEMOKINES; CHEMOKINES, CC; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 0038047045     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02192.x     Document Type: Article

References (40)

1. Sharp JT, Wolfe F, Mitchell DM, Bloch DA. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 1991; 34:660-8.
2. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 1997; 40:598-609.
3. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis: mastermind or workhorse in arthritis? Arthritis Rheum 1997; 40:5-18.
4. Chatham WW, Edberg JC, Kimberley RP. The role of neutrophils in rheumatoid arthritis. In: Firestein GS, Panayi GS, Wollheim FA, eds. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. New York: Oxford University Press, Inc., 2000:101-12.
5. Szekanecz Z, Szegedi G, Koch AE. Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. J Invest Med 1996; 44:124-35.
6. Koch AE, Kunkel SL, Strieter RM. Cytokines in rheumatoid arthritis. J Invest Med 1995; 43:28-38.
7. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353:259-66.
8. Cherwinski HM, Cohn RG, Cheung P et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275:1043-9.
9. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998; 25 (Suppl. 53):20-6.
10. Harris ED. Rationale for combination therapy of rheumatoid arthritis based on pathophysiology. J Rheumatol 1996; 23 (Suppl. 44):2-4.
11. Rau R. Methotrexate. In: Firestein, GS, Panayi, GS, Wollheim, FA, eds. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. New York: Oxford University Press, Inc., 2000:337-50.
12. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard J. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102:322-8.
13. Katschke KJ, Rottman JB, Ruth JH et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 2001; 44:1022-32.
14. Katrib A, Tak PP, Bertouch JV et al. Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology (Oxford) 2001; 40:988-94.
15. Szekanecz Z, Strieter RM, Kunkel SL, Koch AE. Chemokines in rheumatoid arthritis. Springer Semin Immunopathol 1998; 20:115-32.
16. Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S. Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol 1993; 69:83-91.
17. Hachicha M, Rathanaswami P, Schall TJ, McColl SR. Production of monocyte chemotactic protein-1 in human type B synoviocytes. Synergistic effect of tumor necrosis factor alpha and interferon-gamma. Arthritis Rheum 1993; 36:26-34.
18. Pulsatelli L, Dolzani P, Piacentini A et al. Chemokine production by human chondrocytes. J Rheumatol 1999; 26:1992-2001.
19. Ellingsen T, Buus A, Stengaard-Pedersen K. Plasma monocyte chemoattractant protein 1 is a marker for joint inflammation in rheumatoid arthritis. J Rheumatol 2001; 28:41-6.
20. Hayashida K, Nanki T, Girschick H, Yavuz S, Ochi T, Lipsky PE. Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Arthritis Res 2001; 3:118-26.
21. Yoshie O, Imai T, Nomiyama H. Novel lymphocyte-specific CC chemokines and their receptors. J Leukoc Biol 1997; 62:634-44.
22. Godiska R, Chantry D, Raport C et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 1997; 185:1595-604.
23. Bochner BS, Bickel CA, Taylor ML et al. Macrophage-derived chemokine induces human eosinophil chemotaxis in a CC chemokine receptor 3- and CC chemokine receptor 4-independent manner. J Allergy Clin Immunol 1999; 103:527-32.
24. Abi-Younes S, Si-Tahar M, Luster AD. The CC chemokines MDC and TARC induce platelet activation via CCR4. Thromb Res 2001; 101:279-89.
25. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses, effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000; 165:5962-9.
26. Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000; 43:1488-95.
27. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59:841-9.
28. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
29. Smolen JS, Breedveld FC, Eberl G et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995; 38:38-43.
30. Koh ET, Seow A, Pong LY et al. Cross cultural adaptation and validation of the Chinese Health Assessment Questionnaire for use in rheumatoid arthritis. J Rheumatol 1998; 25:1705-8.
31. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36:729-40.
32. Weinblatt ME, Kremer JM, Coblyn JS et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42:1322-8.
33. Fox RI, Herrmann ML, Frangou CG et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999; 93:198-208.
34. Yocum DE. T cells: pathogenic cells and therapeutic targets in rheumatoid arthritis. Semin Arthritis Rheum 1999; 29:27-35.
35. Nardelli B, Morahan DK, Bong GW, Semenuk MA, Kreider BL, Garotta G. Dendritic cells and MPIF-1: chemotactic activity and inhibition of endogenous chemokine production by IFN-gamma and CD40 ligation. J Leukoc Biol 1999; 65:822-8.
36. Nardelli B, Tiffany HL, Bong GW et al. Characterization of the signal transduction pathway activated in human monocytes and dendritic cells by MPIF-1, a specific ligand for CC chemokine receptor 1. J Immunol 1999; 162:435-44.
37. Haque NS, Zhang X, French DL et al. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipo-protein (a) in human vascular endothelial cells. Circulation 2000; 102:786-92.
38. Vicari AP, Figueroa DJ, Hedrick JA et al. TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity 1997; 7:291-301.
39. Al-Mughales J, Blyth TH, Hunter JA, Wilkinson PC. The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines. Clin Exp Immunol 1996; 106:230-6.
40. McInnes IB, al-Mughales J, Field M et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996; 2:175-82.